Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function

Status Completed

Clinical Trial Summary

To evaluate the effects of eslicarbazepine acetate on cognition in comparison with placebo as adjunctive therapy in children aged 6 to 16 years old with refractory partial-onset seizures.

Clinical Trial Description

This will be a 2-part multicentre study in approximately 117 patients. Part I of the study will consist of a 4-week prospective observational baseline period, a 12-week double-blind period (4-week up-titration and 8-week maintenance), and a tapering-off period.

After the screening visit (V1), patients will enter the baseline period. At the end of the baseline period (V2), eligible patients will be randomised in a ratio of 2:1 to receive double-blind treatment with Eslicarbazepine acetate or Placebo in addition to concomitant therapy with 1 or 2 Anti-Epileptic Drugs (AEDs). Concomitant AED therapy will be kept stable during the whole study.

Initial dose of the study treatment will be 10 mg/kg/day. After 2-weeks on 10 mg/kg/day, the dose will be up-titrated to 20 mg/kg/day (maximum 1200 mg/day). After 2 weeks on 20 mg/kg/day, dose will be up-titrated to 30 mg/kg/day (maximum 1200 mg/day) and patients will receive this dose for 8 weeks. If intolerable adverse events (AEs) occur, the patient can be down-titrated to the previous dose (only 1 down-titration step will be allowed) or discontinued. After the 8-week maintenance period, the study treatment will be tapered off in 10 mg/kg/day 2 week steps. However, if a patient experiences an increase in seizure frequency (e.g. more than 100% increase vs. baseline) during tapering-off, the patient can proceed directly to the open-label part of the study (Part II).

After completion of the last 2-week 10 mg/kg/day step, patients will have the option to enter a 1 year open-label treatment (Part II) with Eslicarbazepine acetate (up to 30 mg/kg/day, maximum 1200 mg/day), or will have a 4 week observational follow-up period. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01527513
Study type	Interventional
Source	Bial - Portela C S.A.
Contact
Status	Completed
Phase	Phase 2
Start date	August 2010
Completion date	May 2013

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00982787` - Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy	Phase 2
Completed	`NCT00898560` - Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive	Phase 1
Recruiting	`NCT01735032` - Multimodal Imaging in Pre-surgical Evaluation of Epilepsy	N/A
Completed	`NCT01090934` - Localizing the Epileptogenic Zone With High Resolution Electroencephalography	N/A
Terminated	`NCT00391534` - EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy	Phase 3
Terminated	`NCT01496612` - Buspirone Therapy for Localized Epilepsy	Phase 2
Completed	`NCT00900237` - Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine	Phase 1
Recruiting	`NCT04903314` - Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures	Phase 1
Completed	`NCT01373190` - Thermographic Examination of Skin Temperatures in Individuals With Focal Onset Epilepsy	N/A
Completed	`NCT00894478` - Improving Lesion Detection in Children With Magnetic Resonance Imaging (MRI)-Negative Partial Epilepsy Using Diffusion Tensor Imaging	N/A
Recruiting	`NCT03478852` - Investigating Epilepsy: Screening and Evaluation
Recruiting	`NCT01273129` - Surgery as a Treatment for Medically Intractable Epilepsy
Completed	`NCT00001666` - Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy	N/A
Completed	`NCT00001932` - Serotonin Receptors in Seizure Disorders	N/A
Completed	`NCT00908349` - Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy	Phase 3
Completed	`NCT02076698` - Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy	Phase 3
Completed	`NCT00706160` - Language Mapping in Patients With Epilepsy
Completed	`NCT01397968` - Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures	Phase 2
Completed	`NCT01866111` - A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures	Phase 2
Completed	`NCT00957047` - Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms